As European markets navigate a landscape marked by persistent inflation pressures and geopolitical tensions, the pan-European STOXX Europe 600 Index has recently seen a decline of 1.54%. Amidst this backdrop, small-cap stocks present intriguing opportunities for investors seeking growth potential in undervalued sectors. Identifying promising small caps often involves examining insider actions, which can signal confidence in a company's future prospects despite broader market challenges.

Top 10 Undervalued Small Caps With Insider Buying In Europe

Name PE PS Discount to Fair Value Value Rating Stelrad Group 12.0x 0.7x 39.10% ★★★★★★ Morgan Advanced Materials 11.9x 0.5x 33.98% ★★★★★☆ Tristel 29.0x 4.1x 9.93% ★★★★☆☆ A.G. BARR 19.2x 1.8x 44.22% ★★★★☆☆ Nyab 21.6x 0.9x 33.43% ★★★★☆☆ NOTE 20.0x 1.3x -39.56% ★★★☆☆☆ Absolent Air Care Group 22.1x 1.7x 49.73% ★★★☆☆☆ Fuller Smith & Turner 12.0x 0.9x -33.13% ★★★☆☆☆ Eastnine 18.8x 9.1x 37.36% ★★★☆☆☆ Seeing Machines NA 2.6x 39.56% ★★★☆☆☆

Click here to see the full list of 65 stocks from our Undervalued European Small Caps With Insider Buying screener.

We're going to check out a few of the best picks from our screener tool.

Coats Group

Simply Wall St Value Rating: ★★★★★☆

Overview: Coats Group is a global leader in industrial thread manufacturing, serving the apparel, footwear, and performance materials sectors with a market capitalization of approximately £1.5 billion.

Operations: The company's revenue is primarily derived from three segments: apparel, footwear, and performance materials. Over recent periods, the gross profit margin has shown an upward trend, reaching 36.28% as of June 2024. Operating expenses are a significant cost component, with general and administrative expenses consistently being a substantial part of these costs. The net income margin has also experienced growth in recent years, indicating improved profitability from operations despite fluctuating non-operating expenses.

PE: 21.1x

Coats Group, a European company with small cap characteristics, is making strategic moves to enhance its financial position. Recent insider confidence was demonstrated through share purchases in early 2025. The company plans to exit its US Yarns business, aiming for improved EBIT margins and a more focused portfolio. Despite relying on external borrowing, Coats maintains good cash flow coverage of debt and reported organic revenue growth of 4% from January to April 2025. Earnings are projected to grow over 21% annually.

Take a closer look at Coats Group's potential here in our valuation report. Evaluate Coats Group's historical performance by accessing our past performance report.

Story Continues

LSE:COA Share price vs Value as at Jun 2025

Morgan Advanced Materials

Simply Wall St Value Rating: ★★★★★☆

Overview: Morgan Advanced Materials operates in the sectors of thermal products, performance carbon, and technical ceramics, with a market capitalization of £1.04 billion.

Operations: Morgan Advanced Materials generates revenue primarily from its Thermal Products (£419.90 million), Performance Carbon (£345.70 million), and Technical Ceramics (£337.80 million) segments. The company's gross profit margin has shown variability, with a recent figure of 11.39% as of June 2023, reflecting the relationship between revenue and cost of goods sold over time.

PE: 11.9x

Morgan Advanced Materials, a small-cap player in Europe, demonstrates insider confidence through recent share purchases. Despite relying solely on external borrowing for funding—considered higher risk—the company maintains a solid financial stance with high-quality earnings. The forecasted 18% annual earnings growth highlights potential for future expansion. Recent events like the Annual General Meeting in March 2025 reflect ongoing corporate activities and strategic planning, positioning Morgan Advanced Materials as an intriguing prospect within its industry context.

Navigate through the intricacies of Morgan Advanced Materials with our comprehensive valuation report here. Assess Morgan Advanced Materials' past performance with our detailed historical performance reports.LSE:MGAM Share price vs Value as at Jun 2025

Xvivo Perfusion

Simply Wall St Value Rating: ★★★☆☆☆

Overview: Xvivo Perfusion specializes in developing and commercializing medical technologies for organ transplantation, with a market cap of SEK 8.79 billion.

Operations: The company generates revenue primarily from its Thoracic, Abdominal, and Services segments, with Thoracic being the largest contributor at SEK 576.05 million. The gross profit margin has shown variability over time but was recorded at 74.95% as of December 31, 2024. Operating expenses are significant, driven by sales and marketing along with research and development costs.

PE: 65.4x

Xvivo Perfusion, a European small-cap company, showcases potential with projected earnings growth of 47.85% annually. Despite a net loss of SEK 12.4 million for Q1 2025, sales increased to SEK 218.59 million from the previous year’s SEK 186.02 million, indicating revenue momentum amid financial challenges linked to reliance on external borrowing for funding. Insider confidence is evident as COO & Deputy CEO Lena Hagman recently purchased shares worth approximately SEK 466,500 in April, demonstrating faith in the company's future prospects despite current hurdles like board changes and audit re-elections at their AGM.

Dive into the specifics of Xvivo Perfusion here with our thorough valuation report. Gain insights into Xvivo Perfusion's past trends and performance with our Past report.OM:XVIVO Share price vs Value as at Jun 2025

Summing It All Up

Gain an insight into the universe of 65 Undervalued European Small Caps With Insider Buying by clicking here. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Ready To Venture Into Other Investment Styles?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include LSE:COA LSE:MGAM and OM:XVIVO.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments